Point72 Asset Management, L.P. - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 244 filers reported holding HAEMONETICS CORP in Q2 2022. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.

Quarter-by-quarter ownership
Point72 Asset Management, L.P. ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q1 2023$2,457,675
-91.6%
29,700
-92.1%
0.01%
-92.0%
Q4 2022$29,402,988
-28.8%
373,846
-32.9%
0.10%
-39.4%
Q3 2022$41,275,000
+54.9%
557,539
+36.4%
0.16%
+47.3%
Q2 2022$26,652,000
+41.9%
408,897
+53.7%
0.11%
+34.9%
Q3 2021$18,784,000
+211.1%
266,100
+193.7%
0.08%
+207.4%
Q2 2021$6,038,000
-71.3%
90,600
-52.2%
0.03%
-72.4%
Q1 2021$21,059,000
-36.8%
189,700
-32.4%
0.10%
-39.5%
Q4 2020$33,301,000
-77.1%
280,432
-83.2%
0.16%
-78.2%
Q3 2020$145,408,000
+98.8%
1,666,569
+104.0%
0.74%
+56.0%
Q2 2020$73,155,000
+61.2%
816,825
+79.4%
0.48%
+29.3%
Q1 2020$45,383,000
+10.9%
455,383
+34.0%
0.37%
+72.4%
Q2 2019$40,911,000
-45.6%
339,961
-60.4%
0.21%
-37.2%
Q1 2019$75,181,000
-6.5%
859,410
+6.9%
0.34%
-13.2%
Q4 2018$80,416,000
+10066.4%
803,762
+11548.7%
0.39%
+13000.0%
Q3 2018$791,000
-82.3%
6,900
-88.7%
0.00%
-84.2%
Q1 2018$4,477,000
-83.8%
61,189
-87.2%
0.02%
-84.2%
Q4 2017$27,716,000
+740.1%
477,200
+481.5%
0.12%
+421.7%
Q4 2016$3,299,000
-86.7%
82,058
-88.0%
0.02%
-86.9%
Q3 2016$24,833,000685,8000.18%
Other shareholders
HAEMONETICS CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Nitorum Capital, L.P. 413,122$16,608,0004.78%
Altalis Capital Management LLC 88,055$3,540,0003.97%
RUTABAGA CAPITAL MANAGEMENT LLC/MA 513,619$20,647,0003.54%
Black Creek Investment Management Inc. 1,118,613$44,968,0003.46%
HealthCor Management, L.P. 1,150,000$46,230,0002.61%
Van Berkom & Associates Inc. 1,136,971$45,706,0001.83%
AMERICAN CAPITAL MANAGEMENT INC 567,896$22,829,0001.77%
FULLER & THALER ASSET MANAGEMENT, INC. 2,062,539$82,914,0001.25%
Legato Capital Management LLC 1,336$53,707,0000.97%
HEARTLAND ADVISORS INC 351,314$14,123,0000.78%
View complete list of HAEMONETICS CORP shareholders